Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 4/20 | 0.46 |
| ▸ | GSK3B | P49841 | 11/20 | 0.43 |
| ▸ | CDK2 | P24941 | 8/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1166888 | 0.84 | ADORA2A (0.46) | HCRTR2GSK3BCDK2GAAFBP1 | |
| SCHEMBL14564447 | 0.84 | MEN1 (0.55) | GSK3BCDK2GAAFBP1MEN1 | |
| SCHEMBL3743984 | 0.82 | NOTUM (0.52) | GSK3BCDK2GAA | |
| SCHEMBL8135631 | 0.82 | GSK3B (0.51) | GSK3BCDK2GAAFBP1MEN1 | |
| SCHEMBL27918793 | 0.80 | HCRTR2 (0.40) | HCRTR2GSK3BCDK2GAAFBP1 | |
| SCHEMBL6372051 | 0.79 | ADORA2A (0.60) | GSK3BCDK2GAAFBP1MEN1 | |
| SCHEMBL27905112 | 0.79 | KDM4E (0.47) | GSK3BCDK2GAAFBP1MEN1 | |
| SCHEMBL1931754 | 0.79 | GAA (0.65) | GSK3BCDK2GAAFBP1MEN1 | |
| SCHEMBL1969272 | 0.79 | ADORA2A (0.64) | HCRTR2GSK3BCDK2GAAFBP1 | |
| SCHEMBL2819846 | 0.79 | GSK3B (0.48) | GSK3BCDK2GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HCRTR2 1/4885GSK3B 3215/4885CDK2 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.